Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2023

29-04-2023 | Hepatic Encephalopathy | Original Article

Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy

Authors: Kenneth W. Chow, Brittney M. Ibrahim, Jung J. Yum, An Dang, Long Dang, Kuan-Ting Chen, Nicholas J. Jackson, Sammy Saab

Published in: Digestive Diseases and Sciences | Issue 6/2023

Login to get access

Abstract

Background

Hepatic encephalopathy (HE) is a major cause of mortality and morbidity in patients with cirrhosis. Lactulose non-adherence is one of the most frequently reported precipitants of hospital admission for HE.

Aims

We aimed to identify which factors contribute most to lactulose non-adherence and propose strategies to promote greater adherence and utilization of lactulose.

Methods

Participants in this study consisted of patients with cirrhosis who were taking lactulose for prevention of HE. Subjects were administered the Morisky Adherence Scale 8 (MAS-8) and a customized 16-question survey that assessed barriers to lactulose adherence. Results from the MAS-8 were used to stratify subjects into “adherent” and “non-adherent” groups. Survey responses were compared between groups.

Results

We enrolled 129 patients in our study, of whom 45 were categorized as “adherent and 72 were categorized as “non-adherent.” Barriers to adherence included large volumes of lactulose, high frequency of dosing, difficulty remembering to take the medication, unpleasant taste, and medication side-effects. Most patients (97%) expressed understanding of the importance of lactulose, and 71% of patients felt that lactulose was working to manage their HE. Hospital admission rates for HE was higher in non-adherent patients, although this difference was not statistically significant.

Conclusion

We identified several factors that contribute to lactulose non-adherence among patients treated for HE. Many of these factors are potentially modifiable. Patient and care-giver education are critical to assure adherence. Pharmacists and nurses are an essential but underutilized aspect of education regarding proper medication use.
Appendix
Available only for authorised users
Literature
5.
go back to reference Mukherjee S, John S. Lactulose. In: StatPearls. StatPearls Publishing; 2021. Mukherjee S, John S. Lactulose. In: StatPearls. StatPearls Publishing; 2021.
6.
go back to reference Luo M, Li L, Lu C-Z, Cao W-K. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:1250–1257.CrossRefPubMed Luo M, Li L, Lu C-Z, Cao W-K. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:1250–1257.CrossRefPubMed
7.
go back to reference Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;2016:003044. Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;2016:003044.
8.
go back to reference Pantham G, Post A, Venkat D, Einstadter D, Mullen KD. A new look at precipitants of overt hepatic encephalopathy in cirrhosis. Dig Dis Sci. 2017;62:2166–2173.CrossRefPubMed Pantham G, Post A, Venkat D, Einstadter D, Mullen KD. A new look at precipitants of overt hepatic encephalopathy in cirrhosis. Dig Dis Sci. 2017;62:2166–2173.CrossRefPubMed
9.
go back to reference Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther. 2010;31:1012–1017.PubMed Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther. 2010;31:1012–1017.PubMed
12.
go back to reference Neff G, Zachry W. Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin. Pharmacoeconomics. 2018;36:809–822.CrossRefPubMedPubMedCentral Neff G, Zachry W. Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin. Pharmacoeconomics. 2018;36:809–822.CrossRefPubMedPubMedCentral
14.
go back to reference Lee WY, Ahn J, Kim JH et al. Reliability and validity of a self-reported measure of medication adherence in patients with type 2 diabetes mellitus in Korea. J Int Med Res. 2013;41:1098–1110.CrossRefPubMed Lee WY, Ahn J, Kim JH et al. Reliability and validity of a self-reported measure of medication adherence in patients with type 2 diabetes mellitus in Korea. J Int Med Res. 2013;41:1098–1110.CrossRefPubMed
15.
go back to reference Newman-Casey PA, Robin AL, Blachley T et al. Most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308–1316.CrossRefPubMed Newman-Casey PA, Robin AL, Blachley T et al. Most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308–1316.CrossRefPubMed
16.
go back to reference Okello S, Nasasira B, Muiru AN, Muyingo A. Validity and Reliability of a Self-Reported Measure of Antihypertensive Medication Adherence in Uganda [published correction appears in PLoS ONE. 2017 Oct 31;12: e0187620]. PLoS ONE. 2016;11 :e0158499. Published 2016 Jul 1. https://doi.org/10.1371/journal.pone.0158499 Okello S, Nasasira B, Muiru AN, Muyingo A. Validity and Reliability of a Self-Reported Measure of Antihypertensive Medication Adherence in Uganda [published correction appears in PLoS ONE. 2017 Oct 31;12: e0187620]. PLoS ONE. 2016;11 :e0158499. Published 2016 Jul 1. https://​doi.​org/​10.​1371/​journal.​pone.​0158499
17.
go back to reference Yoshiji H, Karino Y, Suzuki Y et al. Cross-over study in hyperammonemia patients for efficacy, safety, and acceptability of a new lactulose preparation (SK-1202) compared to approved drug: Novel jelly lactulose for medication adherence. Hepatol Res. 2018;48:1178–1183.CrossRefPubMed Yoshiji H, Karino Y, Suzuki Y et al. Cross-over study in hyperammonemia patients for efficacy, safety, and acceptability of a new lactulose preparation (SK-1202) compared to approved drug: Novel jelly lactulose for medication adherence. Hepatol Res. 2018;48:1178–1183.CrossRefPubMed
18.
go back to reference Verloo H, Chiolero A, Kiszio B, Kampel T, Santschi V. Nurse interventions to improve medication adherence among discharged older adults: a systematic review. Age and Ageing 2017;46:747–754.CrossRefPubMed Verloo H, Chiolero A, Kiszio B, Kampel T, Santschi V. Nurse interventions to improve medication adherence among discharged older adults: a systematic review. Age and Ageing 2017;46:747–754.CrossRefPubMed
Metadata
Title
Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy
Authors
Kenneth W. Chow
Brittney M. Ibrahim
Jung J. Yum
An Dang
Long Dang
Kuan-Ting Chen
Nicholas J. Jackson
Sammy Saab
Publication date
29-04-2023
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2023
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-07935-z

Other articles of this Issue 6/2023

Digestive Diseases and Sciences 6/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.